You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-Bcr-Abl

Request The Product List ofBcr-Abl Bcr-Abl

Bcr-Abl tyrosine kinase (Breakpoint cluster region Abelson) is a constitutively activated cytoplasmic tyrosine kinase (TK) and is the underlying cause of chronic myeloid leukemia (CML). To date, imatinib represents the frontline treatment for CML therapy. The development of resistance has prompted the search for novel Bcr-Abl inhibitors.

In Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), the BCR-ABL translocation is the main transforming event; consequently, it is targeted by ABL-tyrosine kinase inhibitors (TKIs), the first of which to be identified was imatinib mesylate. There are now four newer TKIs, three so-called second-generation inhibitors and one third generation inhibitor, all of which are more potent than imatinib in in vitro assays. Since 2001, the Bcr-Abl inhibitor imatinib represents the first-line therapy for CML and also the second-generation Bcr-Abl inhibitor nilotinib and the dual BcrAbl/Src inhibitor dasatinib are now successfully used. Ponatinib, AP24534, by Ariad Pharmaceuticals Inc. has been approved by FDA for the treatment of resistant or imatinib-intolerant CML and Ph+ ALL patients, especially those harboring the T315I mutation. On September 2012, bosutinib received the approval by FDA and in 2013 it was approved also by European Medical Agency.

The search for Bcr-Abl inhibitors is very active. Bcr-Abl inhibitors constitute a very appealing research field that can be expected to expand further.

 

References:

1. Soverini S, et al. Cancer. 2014 Apr 1;120(7):1002-9.

2. Thomas X, et al. Expert Opin Drug Discov. 2016 Nov;11(11):1061-1070.

3. Boer JM, et al. Eur J Cancer. 2017 Sep;82:203-218.

4. Shami PJ, et al. Leukemia. 2012 Feb;26(2):214-24.

5. Wylie AA,et al. Nature. 2017 Mar 30;543(7647):733-737.

 

Cat. No. Product Name CAS No. Information
PC-62147

Asciminib

1492952-76-7 Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells.
PC-60538

CZC-8004

916603-07-1 CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES at low micromolar concentrations..
PC-38592

Adaphostin

241127-58-2 Adaphostin (AG 957 Adamantyl Ester, NSC 680410) is a p210 Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 uM, induces apoptosis in T-lymphoblastic human leukemia cell lines with IC50 of 16.8-216.3 nM.
PC-38393

Flumbatinib

895519-90-1 Flumatinib (HH-GV678) is a potent BCR-ABL/PDGFR/KIT inhibitor, potently inhibits ABL, PDGFR-βand KIT kinase with IC50 of 1.2, 307.6 and 665.5 nM, respectively.
PC-38379

Vodobatinib

1388803-90-4 Vodobatinib (K0706) is a potent, selective inhibitor of BCR-ABL1 with IC50 of 7 nM (wt BCR-ABL1), exhibits activity against most clinically important BCR-ABL1 point mutants (M244V, IC50=22 nM).
PC-73114

PD180970

287204-45-9 PD180970 (PD 180970) is an ATP-competitive inhibitor of p210bcr/abl tyrosine kinase, inhibits autophosphorylation of p210Bcr-Abl with IC50 of 5 nM.
PC-38306

Olverembatinib

1257628-77-5 Olverembatinib (HQP1351, GZD824) is an orally bioavailable multikinase inhibitor targeting a broad spectrum of mutant KIT kinases (KIT-V559D IC50=1. 4 nM).

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com